vs
Side-by-side financial comparison of Ceribell, Inc. (CBLL) and Orchid Island Capital, Inc. (ORC). Click either name above to swap in a different company.
Orchid Island Capital, Inc. is the larger business by last-quarter revenue ($38.5M vs $24.8M, roughly 1.6× Ceribell, Inc.). Orchid Island Capital, Inc. runs the higher net margin — 268.7% vs -54.6%, a 323.3% gap on every dollar of revenue.
Ceribell, Inc. develops and commercializes innovative portable neurodiagnostic medical devices, focused on rapid non-invasive electroencephalogram (EEG) solutions for seizure detection. Its core products serve hospital emergency departments, intensive care units, and long-term care facilities, with primary markets across North America and ongoing global expansion efforts.
Orchid Island Capital, Inc. is a U.S.-based specialty finance company operating as a real estate investment trust. It primarily invests in residential mortgage-backed securities, including agency and non-agency products, targeting consistent risk-adjusted returns for its investors across U.S. fixed income markets.
CBLL vs ORC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.8M | $38.5M |
| Net Profit | $-13.5M | $103.4M |
| Gross Margin | 87.3% | — |
| Operating Margin | -58.9% | — |
| Net Margin | -54.6% | 268.7% |
| Revenue YoY | — | 372.6% |
| Net Profit YoY | — | 1764.9% |
| EPS (diluted) | $-0.35 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $24.8M | $38.5M | ||
| Q3 25 | $22.6M | $26.9M | ||
| Q2 25 | $21.2M | $23.2M | ||
| Q1 25 | $20.5M | $19.7M | ||
| Q3 24 | $17.2M | $340.0K | ||
| Q2 24 | — | $-697.0K | ||
| Q1 24 | — | $-2.5M | ||
| Q4 22 | — | $2.4M |
| Q4 25 | $-13.5M | $103.4M | ||
| Q3 25 | $-13.5M | $72.1M | ||
| Q2 25 | $-13.6M | $-33.6M | ||
| Q1 25 | $-12.8M | $17.1M | ||
| Q3 24 | $-10.4M | $17.3M | ||
| Q2 24 | — | $-5.0M | ||
| Q1 24 | — | $19.8M | ||
| Q4 22 | — | — |
| Q4 25 | 87.3% | — | ||
| Q3 25 | 88.3% | — | ||
| Q2 25 | 88.1% | — | ||
| Q1 25 | 87.9% | — | ||
| Q3 24 | 87.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | -58.9% | — | ||
| Q3 25 | -64.8% | — | ||
| Q2 25 | -70.5% | — | ||
| Q1 25 | -69.3% | — | ||
| Q3 24 | -57.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | -54.6% | 268.7% | ||
| Q3 25 | -59.6% | 267.8% | ||
| Q2 25 | -64.4% | -145.0% | ||
| Q1 25 | -62.4% | 86.9% | ||
| Q3 24 | -60.6% | 5094.1% | ||
| Q2 24 | — | 714.3% | ||
| Q1 24 | — | -794.2% | ||
| Q4 22 | — | — |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.37 | — | ||
| Q2 25 | $-0.38 | — | ||
| Q1 25 | $-0.36 | — | ||
| Q3 24 | $-1.85 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.3M | $665.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $155.3M | $1.4B |
| Total Assets | $195.8M | $11.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $159.3M | $665.9M | ||
| Q3 25 | $168.5M | $583.9M | ||
| Q2 25 | $177.4M | $440.8M | ||
| Q1 25 | $182.7M | $396.4M | ||
| Q3 24 | $14.1M | $322.1M | ||
| Q2 24 | — | $241.0M | ||
| Q1 24 | — | $190.4M | ||
| Q4 22 | — | $205.7M |
| Q4 25 | $155.3M | $1.4B | ||
| Q3 25 | $164.1M | $1.1B | ||
| Q2 25 | $172.2M | $912.0M | ||
| Q1 25 | $180.9M | $855.9M | ||
| Q3 24 | $-136.0M | $656.0M | ||
| Q2 24 | — | $555.9M | ||
| Q1 24 | — | $481.6M | ||
| Q4 22 | — | $438.8M |
| Q4 25 | $195.8M | $11.7B | ||
| Q3 25 | $199.5M | $9.1B | ||
| Q2 25 | $207.7M | $7.6B | ||
| Q1 25 | $213.5M | $7.3B | ||
| Q3 24 | $47.1M | $5.9B | ||
| Q2 24 | — | $4.9B | ||
| Q1 24 | — | $4.2B | ||
| Q4 22 | — | $3.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.8M | $120.4M |
| Free Cash FlowOCF − Capex | $-11.0M | — |
| FCF MarginFCF / Revenue | -44.2% | — |
| Capex IntensityCapex / Revenue | 0.7% | — |
| Cash ConversionOCF / Net Profit | — | 1.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-41.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-10.8M | $120.4M | ||
| Q3 25 | $-11.1M | $28.0M | ||
| Q2 25 | $-7.5M | $18.4M | ||
| Q1 25 | $-11.4M | $25.8M | ||
| Q3 24 | — | $-14.8M | ||
| Q2 24 | — | $19.3M | ||
| Q1 24 | — | $45.0M | ||
| Q4 22 | — | $289.4M |
| Q4 25 | $-11.0M | — | ||
| Q3 25 | $-11.5M | — | ||
| Q2 25 | $-7.6M | — | ||
| Q1 25 | $-11.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | -44.2% | — | ||
| Q3 25 | -50.8% | — | ||
| Q2 25 | -35.9% | — | ||
| Q1 25 | -56.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | 0.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | — | 1.16× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.51× | ||
| Q3 24 | — | -0.86× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.28× | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBLL
| Products | $18.8M | 76% |
| Subscription | $6.0M | 24% |
ORC
Segment breakdown not available.
